Zoetis Inc to Post FY2018 Earnings of $3.10 Per Share, Gabelli Forecasts (ZTS)

Zoetis Inc (NYSE:ZTS) – Equities research analysts at Gabelli lifted their FY2018 earnings per share (EPS) estimates for shares of Zoetis in a report issued on Friday, November 2nd. Gabelli analyst K. Kedra now forecasts that the company will post earnings per share of $3.10 for the year, up from their prior forecast of $3.05. Gabelli also issued estimates for Zoetis’ FY2020 earnings at $4.00 EPS and FY2022 earnings at $4.95 EPS.

Several other research firms have also issued reports on ZTS. JPMorgan Chase & Co. boosted their price target on Zoetis from $100.00 to $101.00 and gave the company an “overweight” rating in a report on Friday. Cantor Fitzgerald reissued an “overweight” rating and set a $105.00 price target (up previously from $98.00) on shares of Zoetis in a report on Wednesday, October 17th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a report on Wednesday, October 17th. Morgan Stanley set a $100.00 price target on Zoetis and gave the company a “hold” rating in a report on Friday. Finally, Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a report on Tuesday, August 21st. They noted that the move was a valuation call. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Zoetis has a consensus rating of “Buy” and a consensus target price of $93.19.

NYSE:ZTS opened at $92.77 on Monday. Zoetis has a 52-week low of $67.44 and a 52-week high of $96.57. The company has a debt-to-equity ratio of 2.50, a current ratio of 4.38 and a quick ratio of 2.92. The stock has a market cap of $44.70 billion, a price-to-earnings ratio of 38.65, a P/E/G ratio of 1.78 and a beta of 0.97.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 1st. The company reported $0.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.06. Zoetis had a return on equity of 77.52% and a net margin of 20.35%. The company had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same quarter in the previous year, the company posted $0.65 earnings per share. Zoetis’s revenue was up 9.9% compared to the same quarter last year.

Institutional investors have recently made changes to their positions in the company. Keybank National Association OH lifted its position in shares of Zoetis by 180.8% in the second quarter. Keybank National Association OH now owns 199,773 shares of the company’s stock valued at $17,019,000 after acquiring an additional 128,634 shares in the last quarter. Chartwell Investment Partners LLC lifted its position in shares of Zoetis by 7.0% in the second quarter. Chartwell Investment Partners LLC now owns 76,888 shares of the company’s stock valued at $6,550,000 after acquiring an additional 5,000 shares in the last quarter. FMR LLC lifted its position in shares of Zoetis by 26.3% in the second quarter. FMR LLC now owns 1,654,795 shares of the company’s stock valued at $140,972,000 after acquiring an additional 344,241 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Zoetis by 8.7% in the second quarter. Bank of New York Mellon Corp now owns 5,262,461 shares of the company’s stock valued at $448,309,000 after acquiring an additional 422,856 shares in the last quarter. Finally, Worldquant Millennium Quantitative Strategies LLC purchased a new position in shares of Zoetis in the second quarter valued at about $20,475,000. Institutional investors and hedge funds own 89.75% of the company’s stock.

In other news, insider Roman Trawicki sold 8,266 shares of the business’s stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of $92.53, for a total value of $764,852.98. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Juan Ramon Alaix sold 135,000 shares of the business’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $91.55, for a total value of $12,359,250.00. The disclosure for this sale can be found here. Insiders sold 208,467 shares of company stock worth $19,071,625 over the last 90 days. Company insiders own 0.35% of the company’s stock.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Tuesday, November 20th will be given a $0.126 dividend. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.54%. Zoetis’s payout ratio is 20.83%.

Zoetis Company Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Featured Article: Stock Symbol

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply